JP2018519803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519803A5 JP2018519803A5 JP2017560331A JP2017560331A JP2018519803A5 JP 2018519803 A5 JP2018519803 A5 JP 2018519803A5 JP 2017560331 A JP2017560331 A JP 2017560331A JP 2017560331 A JP2017560331 A JP 2017560331A JP 2018519803 A5 JP2018519803 A5 JP 2018519803A5
- Authority
- JP
- Japan
- Prior art keywords
- ser
- arg
- tyr
- leu
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 123
- 229920001184 polypeptide Polymers 0.000 claims description 119
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 119
- 230000004927 fusion Effects 0.000 claims description 103
- 102100032530 Glypican-3 Human genes 0.000 claims description 42
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 42
- 102000019298 Lipocalin Human genes 0.000 claims description 37
- 108050006654 Lipocalin Proteins 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 125000000539 amino acid group Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 230000006044 T cell activation Effects 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 230000007783 downstream signaling Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000004073 interleukin-2 production Effects 0.000 claims description 4
- 230000004988 N-glycosylation Effects 0.000 claims description 3
- 230000005867 T cell response Effects 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 229950005972 urelumab Drugs 0.000 claims description 2
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 claims 11
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 claims 8
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 claims 8
- 108010055341 glutamyl-glutamic acid Proteins 0.000 claims 8
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 claims 6
- 108010068380 arginylarginine Proteins 0.000 claims 6
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 claims 3
- 108010077112 prolyl-proline Proteins 0.000 claims 3
- 108010028295 histidylhistidine Proteins 0.000 claims 2
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 claims 1
- 102000010956 Glypican Human genes 0.000 claims 1
- 108050001154 Glypican Proteins 0.000 claims 1
- 108050007237 Glypican-3 Proteins 0.000 claims 1
- HVWXAQVMRBKKFE-UGYAYLCHSA-N Ile-Asp-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HVWXAQVMRBKKFE-UGYAYLCHSA-N 0.000 claims 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 claims 1
- 108010001267 Protein Subunits Proteins 0.000 claims 1
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 claims 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims 1
- 108010054155 lysyllysine Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 description 7
- 238000012286 ELISA Assay Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167927 | 2015-05-18 | ||
| EP15167927.1 | 2015-05-18 | ||
| EP16150508 | 2016-01-08 | ||
| EP16150508.6 | 2016-01-08 | ||
| PCT/EP2016/061071 WO2016184882A1 (en) | 2015-05-18 | 2016-05-18 | Anti-cancer fusion polypeptide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519803A JP2018519803A (ja) | 2018-07-26 |
| JP2018519803A5 true JP2018519803A5 (OSRAM) | 2019-06-20 |
| JP6947642B2 JP6947642B2 (ja) | 2021-10-13 |
Family
ID=56134305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560331A Active JP6947642B2 (ja) | 2015-05-18 | 2016-05-18 | 抗がん性融合ポリペプチド |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10913778B2 (OSRAM) |
| EP (2) | EP4219535A1 (OSRAM) |
| JP (1) | JP6947642B2 (OSRAM) |
| KR (1) | KR102685748B1 (OSRAM) |
| CN (1) | CN108112253B (OSRAM) |
| AU (1) | AU2016262845B2 (OSRAM) |
| CA (1) | CA2980838A1 (OSRAM) |
| DK (1) | DK3298030T5 (OSRAM) |
| ES (1) | ES2938525T3 (OSRAM) |
| FI (1) | FI3298030T3 (OSRAM) |
| HR (1) | HRP20230145T1 (OSRAM) |
| HU (1) | HUE061108T2 (OSRAM) |
| LT (1) | LT3298030T (OSRAM) |
| MX (1) | MX390894B (OSRAM) |
| PL (1) | PL3298030T3 (OSRAM) |
| RS (1) | RS64002B1 (OSRAM) |
| RU (2) | RU2754466C2 (OSRAM) |
| SG (1) | SG11201707426SA (OSRAM) |
| SI (1) | SI3298030T1 (OSRAM) |
| SM (1) | SMT202300026T1 (OSRAM) |
| WO (1) | WO2016184882A1 (OSRAM) |
| ZA (1) | ZA201706061B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| US11261221B2 (en) * | 2015-05-04 | 2022-03-01 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| CN108348573A (zh) | 2015-07-15 | 2018-07-31 | 皮里斯制药有限公司 | Lag-3特异性的新型蛋白 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| CA3047070A1 (en) * | 2017-01-03 | 2018-07-12 | F.Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| WO2018127710A1 (en) | 2017-01-06 | 2018-07-12 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| MX2019008434A (es) * | 2017-01-18 | 2019-11-11 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina con afinidad de unión por lag-3. |
| WO2018134279A1 (en) * | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptides specific for lag-3 and pd-1 |
| CN111683968B (zh) | 2017-11-13 | 2024-07-05 | 克雷森多生物制剂有限公司 | 结合至cd137和psma的分子 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| CN112004535A (zh) | 2018-03-26 | 2020-11-27 | 4Sc股份公司 | 用于癌症疗法的包括hdac抑制剂和cd137激动剂的组合 |
| AU2019315703A1 (en) * | 2018-07-31 | 2020-12-10 | Les Laboratoires Servier | Novel fusion protein specific for CD137 and PD-L1 |
| US12486330B2 (en) * | 2019-02-26 | 2025-12-02 | Pieris Pharmaceuticals Gmbh | Fusion proteins specific for CD137 and GPC3 |
| CN113939307A (zh) * | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| EP3952996A1 (en) * | 2019-04-12 | 2022-02-16 | F. Hoffmann-La Roche AG | Bispecific antigen binding molecules comprising lipocalin muteins |
| TW202337914A (zh) * | 2019-04-23 | 2023-10-01 | 南韓商Ｌｇ化學股份有限公司 | 融合多肽及其用途與製備方法、核酸分子、重組載體、重組細胞以及用於增強生長/分化因子15或其功能變體的活體內穩定性的方法 |
| PE20220231A1 (es) * | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| TWI862640B (zh) * | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| WO2023036043A1 (zh) * | 2021-09-09 | 2023-03-16 | 广东东阳光药业有限公司 | 抗癌结合分子及其应用 |
| TW202428603A (zh) * | 2022-09-21 | 2024-07-16 | 美商思進公司 | 新穎的cd137及cd228特異性融合蛋白 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3779221D1 (de) | 1986-08-19 | 1992-06-25 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| WO1995031479A1 (en) | 1994-05-18 | 1995-11-23 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| PL192364B1 (pl) | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US7235520B2 (en) | 2000-09-21 | 2007-06-26 | University Of Massachusetts | Method of inducing apoptosis in lymphoid cells |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| US20070212703A1 (en) | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| WO2007137170A2 (en) | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
| AU2007280398B2 (en) | 2006-08-01 | 2012-05-10 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| CN101516907B (zh) | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| RS54624B1 (sr) | 2007-07-17 | 2016-08-31 | E. R. Squibb & Sons, L.L.C. | Monoklonska antitela protiv glipikana-3 |
| CA2702590A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| EP2313430B1 (en) | 2008-06-24 | 2018-05-02 | Technische Universität München | Muteins of hngal and related proteins with affinity for a given target |
| US9549968B2 (en) | 2009-12-07 | 2017-01-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target |
| CA2808392C (en) | 2010-08-16 | 2020-03-10 | Pieris Ag | Binding proteins for hepcidin |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| DK2640740T3 (en) | 2010-11-15 | 2017-06-26 | Pieris Pharmaceuticals Gmbh | MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) |
| US9522940B2 (en) * | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| US20140179560A1 (en) * | 2012-12-10 | 2014-06-26 | Fred Hutchinson Cancer Research Center | Drug discovery methods and platforms |
| EP2948475A2 (en) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| CN104140974B (zh) * | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| MX380176B (es) * | 2014-04-07 | 2025-03-12 | Chugai Pharmaceutical Co Ltd | Molecula ligada a antigeno inmunoactivada. |
| SG10201906859PA (en) | 2015-01-28 | 2019-08-27 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| AR103714A1 (es) | 2015-02-18 | 2017-05-31 | Sanofi Sa | Proteínas específicas para pioverdina y pioquelina |
| US11261221B2 (en) * | 2015-05-04 | 2022-03-01 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| CN107636014B (zh) | 2015-05-04 | 2021-12-07 | 皮里斯制药有限公司 | 抗癌融合多肽 |
| CN107787327B (zh) | 2015-05-18 | 2022-02-08 | 皮里斯制药有限公司 | 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白 |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2016
- 2016-05-18 FI FIEP16729794.4T patent/FI3298030T3/fi active
- 2016-05-18 EP EP22216061.6A patent/EP4219535A1/en active Pending
- 2016-05-18 LT LTEPPCT/EP2016/061071T patent/LT3298030T/lt unknown
- 2016-05-18 WO PCT/EP2016/061071 patent/WO2016184882A1/en not_active Ceased
- 2016-05-18 CN CN201680028941.3A patent/CN108112253B/zh active Active
- 2016-05-18 PL PL16729794.4T patent/PL3298030T3/pl unknown
- 2016-05-18 KR KR1020177035641A patent/KR102685748B1/ko active Active
- 2016-05-18 MX MX2017014716A patent/MX390894B/es unknown
- 2016-05-18 SM SM20230026T patent/SMT202300026T1/it unknown
- 2016-05-18 AU AU2016262845A patent/AU2016262845B2/en active Active
- 2016-05-18 SG SG11201707426SA patent/SG11201707426SA/en unknown
- 2016-05-18 US US15/575,309 patent/US10913778B2/en active Active
- 2016-05-18 JP JP2017560331A patent/JP6947642B2/ja active Active
- 2016-05-18 EP EP16729794.4A patent/EP3298030B1/en active Active
- 2016-05-18 HR HRP20230145TT patent/HRP20230145T1/hr unknown
- 2016-05-18 RU RU2017135539A patent/RU2754466C2/ru active
- 2016-05-18 RU RU2021119777A patent/RU2021119777A/ru unknown
- 2016-05-18 DK DK16729794.4T patent/DK3298030T5/da active
- 2016-05-18 RS RS20230084A patent/RS64002B1/sr unknown
- 2016-05-18 CA CA2980838A patent/CA2980838A1/en active Pending
- 2016-05-18 SI SI201631659T patent/SI3298030T1/sl unknown
- 2016-05-18 ES ES16729794T patent/ES2938525T3/es active Active
- 2016-05-18 HU HUE16729794A patent/HUE061108T2/hu unknown
-
2017
- 2017-09-06 ZA ZA2017/06061A patent/ZA201706061B/en unknown
-
2021
- 2021-02-05 US US17/169,209 patent/US11919931B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519803A5 (OSRAM) | ||
| JP2018515085A5 (OSRAM) | ||
| JP2018526989A5 (OSRAM) | ||
| RU2017135539A (ru) | Слитый полипептид с противораковой активностью | |
| RU2017135596A (ru) | Слитый полипептид с противораковой активностью | |
| RU2018107991A (ru) | Новый слитый полипептид, специфичный в отношении lag-3 и pd-1 | |
| JP2017527272A5 (OSRAM) | ||
| CN110234355B (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| RU2017135599A (ru) | Белки, специфичные в отношении cd137 | |
| JP7482488B2 (ja) | Ｃｄ１３７とｐｄ－ｌ１に特異的な新規融合タンパク質 | |
| RU2015129640A (ru) | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 | |
| Mezo et al. | Atrial natriuretic peptide-Fc, ANP-Fc, fusion proteins: semisynthesis, in vitro activity and pharmacokinetics in rats | |
| RS55609B1 (sr) | Fc fuzioni proteini koji sadrže nove linkere ili aranžmane | |
| JP2015524799A5 (OSRAM) | ||
| JP2011501951A5 (OSRAM) | ||
| JP2018532372A5 (OSRAM) | ||
| JP2019502694A (ja) | 二特異性抗体基幹 | |
| JP2017518748A5 (OSRAM) | ||
| EA012507B1 (ru) | Высокоаффинные мелан-а т-клеточные рецепторы | |
| JP2019506140A5 (OSRAM) | ||
| JP2019505565A5 (OSRAM) | ||
| Plaksin et al. | A three-domain T cell receptor is biologically active and specifically stains cell surface MHC/peptide complexes. | |
| TW202233694A (zh) | 雙特異性抗體 | |
| KR20210091220A (ko) | 부착된 세포에 직접 신호를 보내지 않는 비-천연 nkg2d 수용체 | |
| JPWO2020025659A5 (OSRAM) |